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Abstract 
Background: Reduced heart rate variability (HRV), a measure of cardiac autonomic function, is associated with 
an increased risk of cardiovascular disease (CVD) and mortality. Glucose homeostasis measures are associated with 
reduced cardiac autonomic function among those with diabetes, but inconsistent associations have been reported 
among those without diabetes. This study aimed to examine the association of glucose homeostasis measures with 
cardiac autonomic function among diverse Hispanic/Latino adults without diabetes.
Methods: The Hispanic community Health Study/Study of Latinos (HCHS/SOL; 2008–2011) used two-stage area 
probability sampling of households to enroll 16,415 self-identified Hispanics/Latinos aged 18–74 years from four USA 
communities. Resting, standard 12-lead electrocardiogram recordings were used to estimate the following ultrashort-
term measures of HRV: RR interval (RR), standard deviation of all normal to normal RR (SDNN) and root mean square 
of successive differences in RR intervals (RMSSD). Multivariable regression analysis was used to estimate associa-
tions between glucose homeostasis measures with HRV using data from 11,994 adults without diabetes (mean age 
39 years; 52 % women).
Results: Higher fasting glucose was associated with lower RR, SDNN, and RMSSD. Fasting insulin and the homeosta-
sis model assessment of insulin resistance was negatively associated with RR, SDNN, and RMSSD, and the association 
was stronger among men compared with women. RMSSD was, on average, 26 % lower in men with higher fasting 
insulin and 29 % lower in men with lower insulin resistance; for women, the corresponding estimates were smaller at 
4 and 9 %, respectively. Higher glycated hemoglobin was associated with lower RR, SDNN, and RMSSD in those with 
abdominal adiposity, defined by sex-specific cut-points for waist circumference, after adjusting for demographics and 
medication use. There were no associations between glycated hemoglobin and HRV measures among those without 
abdominal adiposity.
Conclusions: Impairment in glucose homeostasis was associated with lower HRV in Hispanic/Latino adults without 
diabetes, most prominently in men and individuals with abdominal adiposity. These results suggest that reduced 
cardiac autonomic function is associated with metabolic impairments before onset of overt diabetes in certain 
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Background
Metabolic dysregulation is associated with reduced car-
diac autonomic function [1] and is implicated in the 
development of cardiac autonomic neuropathy among 
those with type 2 diabetes [2, 3]. Cardiac autonomic 
function can be non-invasively measured by heart rate 
variability (HRV). Reduced HRV has been associated 
with cardiometabolic risk factors [4] and the metabolic 
syndrome [5–7], suggesting that autonomic dysfunction 
may occur before overt diabetes. In a murine model, dia-
betic and infarcted groups showed decreased HRV com-
pared to controls [8].
Impairment in glucose homeostasis is associated with 
reduced autonomic function among people with diabe-
tes [4, 9–12]; however, the association has not been suf-
ficiently examined among those without diabetes [9, 13]. 
Prior studies did not include a comprehensive set of glu-
cose homeostasis measures and were primarily among 
Caucasian samples. While Hispanic/Latino adults in the 
United States have a high burden of cardio metabolic risk 
factors [14], the metabolic syndrome [15], and high risk 
for diabetes [16], the association of glucose homeostasis 
measures and HRV has not been examined among His-
panic/Latino adults without diabetes.
The aim of this study, therefore, was to examine the 
associations of fasting insulin, fasting glucose, glycated 
hemoglobin (HbA1c), and insulin resistance with cardiac 
autonomic function as estimated by ultra-short term 
measures of HRV among participants without diabetes 
in the Hispanic Community Health Study/Study of Lati-
nos (HCHS/SOL). Understanding factors associated with 
HRV among this population with a high burden of car-
diometabolic risk could provide insight into mechanisms 
of reduced cardiac autonomic function and the potential 
to identify individuals at risk for metabolic disease before 
autonomic control is manifestly impaired.
Methods
Study cohort
HCHS/SOL is a multicenter epidemiologic cohort study 
examining chronic disease, risk and prevalence in 16,415 
Hispanics/Latinos aged 18–74  years of Mexican, Cen-
tral American, Cuban, Dominican, Puerto Rican, South 
American and other heritage groups. Details concern-
ing the sampling strategy have been published elsewhere 
[17, 18]. Briefly, the HCHS/SOL target population was 
defined as all non-institutionalized self-identified His-
panic/Latino adults aged 18–74 years residing in defined 
geographical areas (census block groups) at the follow-
ing four field centers: Bronx, NY, Chicago, IL, Miami, 
FL, and San Diego, CA. Participants were selected from 
the target population using a two-stage area household 
probability sampling approach. Over-sampling at both 
stages of sample selection was used to increase the like-
lihood that a selected address yielded an eligible house-
hold and to increase the proportion of participants ages 
45–74 years (n = 9714, 59.2 %). All participants provided 
written informed consent, and the study was approved by 
the Institutional Review Boards at all field centers, coor-
dinating center, central labs, and reading centers.
Participants on whom an electrocardiogram (ECG) 
was not performed (n =  183), had diabetes (n =  2868), 
were using antiarrhythmic medication or self-reported 
using medication for abnormal heart rhythm (n = 265), 
were age >75 years (n = 7), or were missing information 
on key variables (n = 277) were excluded from the analy-
sis. Key variables included Hispanic/Latino background, 
smoking status, waist circumference (WC), body mass 
index (BMI), fasting insulin, fasting glucose, and HbA1c. 
Additionally, guided by the current recommendations for 
measurement of HRV [19], we also excluded participants 
not in sinus rhythm or with rhythm disorders (n = 693), 
and low quality ECGs to ensure the accuracy and quality 
of the HRV measures (n = 128). Thus, these analyses are 
based on data from 11,994 participants (52 % women).
Data collection
Study examinations were conducted at field centers by 
certified study personnel following a standardized proto-
col. The details of the examination have been previously 
described [18]. In brief, participants were asked to fast, 
not smoke 12 h before the examination, refrain from vig-
orous physical activity the morning of the examination, 
and bring all prescription and nonprescription medica-
tion taken by them in the past 4 weeks. The medications 
were inventoried and therapeutically classified using a 
Master Drug Data Base (Medispan MDDB©) supple-
mented with Spanish-language brand and generic name 
equivalents from Lexi-Comp Online™ and OVID© Mar-
tindale. Study personnel administered questionnaires to 
collect medical history, demographic factors, education, 
income, country of origin, length of residence in the 
subgroups, offering clues for the pathophysiologic processes involved as well as opportunity for identification of 
those at high risk before autonomic control is manifestly impaired.
Keywords: Autonomic function, Insulin resistance, Type 2 diabetes mellitus, Parasympathetic and sympathetic 
nervous system, Cohort study
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United States, language preference, and lifestyle infor-
mation. Anthropometric measurements included body 
weight (kg), height (cm), WC and calculated BMI. Three 
sitting blood pressure measurements were taken with an 
automatic sphygmomanometer (OMRON HEM-907 XL, 
Omron Healthcare Co. Ltd., Kyoto, Japan) after a 5 min 
rest and the last two measurements were averaged. Blood 
and urine specimens were collected and shipped to the 
HCHS/SOL Central Laboratory to be assayed, i.e. for 
total cholesterol, high-density lipoprotein, low-density 
lipoprotein, triglycerides, and fasting glucose and insu-
lin. Hypertension was defined as systolic blood pressure 
≥140 mm/Hg, diastolic blood pressure ≥90 mm/Hg, or 
self-reported use of anti-hypertensive medication. Dia-
betes was defined according to American Diabetes Asso-
ciation guidelines [20] as an HbA1c0 ≥6.5  %, post-oral 
glucose tolerance test glucose ≥200  mg/dL, fasting glu-
cose ≥126  mg/dL, non-fasting glucose ≥200  mg/dL, or 
self-reported use of anti-diabetic medication. Abdomi-
nal adiposity was defined as WC ≥102 cm for men and 
≥88  cm for women. Prevalent coronary heart disease 
included ECG reports of possible myocardial infarction 
(major Q wave abnormalities and minor Q,QS waves 
with ST,T abnormalities) as well as self-report of heart 
attack or procedure (angioplasty, stent, bypass). Heart 
failure was self-reported, but not conformed.
Electrocardiography
Resting, standard, 12-lead, 10 s ECGs were recorded fol-
lowing a standardized protocol. The participants were 
supine, breathing freely, and instructed not to talk dur-
ing the recording. Study personnel positioned the elec-
trodes using a chest electrode locator [21, 22]. ECGs 
were recorded using the GE MAC 1200 electrograph 
(GE, Milwaukee, Wisconsin) with a 10 mm/mV calibra-
tion at a speed of 25  mm/s. The Epidemiology Cardiol-
ogy Research Center (EPICARE; Wake Forest School of 
Medicine, Winston Salem, NC) centrally processed the 
ECGs using the GE 12-SL Marquette Version 2001 (GE, 
Milwaukee, Wisconsin).
The automatically calculated ultra-short term, time 
domain measures of HRV included the median dura-
tion of the RR interval across all twelve leads as com-
puted from heart rate, RR (ms)  =  60,000  ms/heart 
rate (bpm); the standard deviation of all normal to 
normal RR intervals that indicates total HRV, SDNN 
(ms) =
{[∑
n
j=1
(
RRmean − RRj
)2]/
(n− 1)
}0.5
 and 
the root mean square of successive differences in 
all normal to normal RR intervals that indicates the 
degree the RR interval changes between adjacent beats, 
RMSSD(ms) =
{[∑ n
j=1
(
RRj + 1 − RRj
)2]/
n
}0.5
.
Statistical methods
All analyses used complex survey methods and were 
weighted to account for design effects, cluster sampling 
and the use of stratification in sample selection [18]. 
Means and prevalence rates are therefore presented as 
weighted statistics to adjust for potential bias due to dif-
ferential nonresponse at the household and person levels. 
We estimated the mean and 95 % confidence interval (CI) 
of RMSSD, SDNN and RR interval by demographic char-
acteristics, and quartiles of glucose homeostasis meas-
ures stratified by sex. Following the recommendations of 
Rothman [23], effect sizes and confidence intervals were 
presented in place of p values and significance testing.
Multivariable linear regression analyses were used to 
estimate associations between exposures (fasting insu-
lin, fasting glucose, HbA1c, and insulin resistance com-
puted according to the homeostasis model assessment 
of insulin resistance (HOMA-IR)) and outcomes (SDNN, 
RMSSD and RR). Separate models were constructed for 
each exposure-outcome pair and exposures were not 
adjusted for other glucose homeostasis measures. The 
adjustment variables considered in all models included 
sex, age groups (18–24, 25–34, 35–44, 45–54, 55–64, and 
65+ years old), Hispanic/Latino background, field center, 
continuous BMI, continuous waist circumference, cur-
rent smoking, heart rate modifying drugs (beta-blockers, 
non-hydropyridine calcium channel blockers, and sym-
pathomimetics), and the interactions between glucose 
homeostasis measures with gender, age and abdominal 
adiposity. In sensitivity analyses, we adjusted for self-
reported physical activity and alcohol consumption. For 
simplicity, interactions were selected based on model 
fit using adjusted R2 values for RMSSD. Interactions 
were selected if adjusted R2 values increased model fit 
by at least 0.001. When interaction terms were selected, 
we reported stratified results. For HbA1c, the waist cir-
cumference interaction was selected but categorized as 
WC ≥102 cm for men and ≥88 cm for women to indi-
cate abdominal adiposity for ease of interpretation. For 
anthropometric measures, WC was chosen as a covari-
ate based on a slightly higher adjusted R2 value com-
pared with the model with BMI (difference in adjusted 
R2  ≈  0.00013). The best fitting models for SDNN were 
similar and the same model was used for RR interval for 
comparability. Analyses were conducted using complex 
survey procedures in SAS (version 9.3, SAS Institute, 
Inc., Cary, NC) and SUDAAN (release 11.0.0, Research 
Triangle Institute, Research Triangle Park, NC).
Results
About half of the HCHS/SOL target population for this 
study was comprised of women and the mean age was 
38.8  years (Table  1). Almost 37  % of the HCHS/SOL 
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target population was obese and 51  % had abdomi-
nal adiposity. Individuals of Mexican background were 
the largest Hispanic/Latino background group at 38  % 
of the HCHS/SOL target population. Men had an 8  % 
lower mean RMSSD, similar SDNN, and 4 % higher RR 
compared with women (Table  2). Individuals taking 
beta-blockers and non-hydropyridine calcium channel 
blockers had 35–66  % higher mean RMSSD and SDNN 
than non-users, but those taking beta-blockers had a 5 % 
lower mean RR. Mean RMSSD and SDNN was lower 
by 53–56  % between age groups 18–24 and 65+ years. 
All measures were 4–11  % lower among those without 
abdominal adiposity versus those with abdominal adi-
posity. Those with obesity had 4 % lower RR but similar 
RMSSD and SDNN versus non-obese individuals.
HRV and RR varied by quartiles of glucose homeosta-
sis measures (Fig. 1). Trends for RMSSD and SDNN were 
very similar. Comparing those in quartile 4 to those in 
quartile 1 for fasting insulin and HOMA-IR, the mean 
RMSSD was 27 and 29 % lower, respectively, among men. 
But for women, the mean differences were much smaller 
(4 and 9 %, Fig. 1). Comparing those in quartile 4 to those 
in quartile 1 of fasting glucose, the mean RMSSD was 
27 % lower in men and 29 % lower in women. Trends for 
SDNN were similar to those of RMSSD. Subgroup trend 
differences for RR interval were much less pronounced. 
For example, comparing those in quartile 4 to those in 
quartile 1 of fasting insulin, the mean RR interval was 
lower by 10 % in men and 8 % in women.
After adjustment for gender, age, Hispanic/Latino 
background, field center, and medication use, the asso-
ciation of fasting glucose with RMSSD was greatly 
reduced (from −0.65 to −0.20  mm change in RMSSD 
for each mg/dL increase in fasting glucose; Table 3). The 
association of fasting glucose with RR was more pro-
nounced after adjustment for all covariates (β = −1.55 
vs −0.80). Fasting insulin was negatively associated with 
all HRV measures, and the association was stronger 
among men compared with women. The multivariable 
models for fasting insulin were similar to unadjusted 
models (β = −0.45 vs β = −0.44 for men, β = −0.06 
vs β = −0.14 for women). HbA1c was negatively asso-
ciated with RMSSD among individuals with abdominal 
adiposity, defined by sex-specific cut-points for WC, 
but not among those without abdominal adiposity. 
While the unadjusted subgroup effects for HbA1c were 
similar for individuals with and without abdominal adi-
posity, after adjusting for gender, age, Hispanic/Latino 
background, field center, and medication use, differ-
ences in subgroups emerged for all HRV measures. The 
association of HbA1c and SDNN were similar to that of 
RMSSD. After adjustment, there was little or no asso-
ciation between HbA1c and RR among those without 
abdominal adiposity, but there was a 22.9  ms decrease 
in RR for each unit increase in HbA1c among those with 
abdominal adiposity. As with fasting insulin, HOMA-IR 
was associated with all HRV measures in both men and 
women, but the association was slightly stronger among 
men. Adjusting for physical activity and current weekly 
alcohol consumption did not alter the results (data not 
shown).
Discussion
Our study contributes new information to the field by 
evaluating the cross-sectional association of multiple 
Table 1 Demographic characteristics
The Hispanic Community Health Study/Study of Latinos (HCHS/SOL) baseline 
examination (2008–2011)
Abdominal adiposity (waist circumference ≥102 cm for men and ≥88 cm for 
women)
Characteristic N % or Mean 95 % CI
Male (%) 4833 48.11 (46.79, 49.42)
Age group (%)
 18–24 1444 18.94 (17.73, 20.21)
 25–34 1819 24.63 (23.25, 26.06)
 35–44 2461 23.03 (21.81, 24.30)
 45–54 3562 18.01 (17.03, 19.02)
 55–64 2106 10.34 (9.61, 11.12)
 65+ 602 5.05 (4.47, 5.70)
Hispanic background (%)
 Mexican/Mexican American 4784 38.13 (34.90, 41.46)
 Puerto Rican 1809 15.09 (13.58, 16.74)
 Cuban 1753 19.61 (16.54, 23.08)
 Dominican 1084 10.02 (8.68, 11.55)
 Central American 1320 7.59 (6.48, 8.86)
 South American 854 5.28 (4.63, 6.02)
 Other 390 4.28 (3.68, 4.96)
Body mass index (BMI; kg/m2) 28.88 (28.68, 29.08)
Waist circumference (cm) 95.90 (95.44, 96.36)
Obese (BMI ≥ 30 kg/m2) 4597 36.86 (35.37, 38.38)
Abdominal adiposity 6818 51.44 (49.82, 53.05)
Systolic blood pressure (mmHg) 118.32 (117.85, 118.79)
Diastolic blood pressure (mmHg) 71.79 (71.43, 72.15)
Fasting glucose (mg/dL) 93.51 (93.28, 93.74)
Fasting insulin (mU/L) 12.06 (11.78, 12.34)
HbA1c (%) 5.41 (5.40, 5.42)
HOMA-IR (index) 2.83 (2.76, 2.90)
Current smoking 2382 21.86 (20.60, 23.17)
Coronary heart disease 416 3.19 (2.71, 3.75)
Self-reported heart failure 132 0.87 (0.68, 1.10)
Beta blocker use 520 3.24 (2.86, 3.66)
Non-hydropyridine calcium channel 
blocker use
300 1.98 (1.63, 2.41)
Sympathomimetic medication use 441 3.50 (3.01, 4.07)
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glucose homeostasis measures with cardiac autonomic 
function in a diverse population of Hispanic/Latino 
adults. In this cross-sectional study, higher fasting glu-
cose was associated with lower HRV, as assessed by 
several HRV measures, in all subgroups; higher fasting 
insulin and HOMA-IR were associated with lower HRV 
particularly in men; and higher HbA1c was associated 
with lower HRV in individuals with abdominal adipos-
ity. These results suggest that reduced cardiac autonomic 
function occurs among those with metabolic impair-
ments even before the onset of overt diabetes. The asso-
ciation was more pronounced among men and those with 
abdominal adiposity, defined by sex-specific cut-points 
for waist circumference.
Prior studies of glucose homeostasis measures and cardiac 
autonomic function
Our findings are in agreement with prior studies among 
people without diabetes showing associations between 
glucose homeostasis measures with reduced cardiac 
autonomic function, although results are inconsist-
ent across glucose homeostasis measures [4, 5, 9, 13]. 
The atherosclerosis risk in communities study reported 
weak, inverse cross-sectional associations between fast-
ing glucose and insulin quintiles with RMSSD and RR 
among people without diabetes [9]. Insulin quintiles were 
negatively associated with SDNN, whereas no associa-
tions were seen between glucose quintiles and SDNN. In 
contrast, fasting glucose was negatively associated with 
Table 2 Mean and 95 % confidence interval (CI) of RMSSD, SDNN and RR interval by demographic characteristics
CI confidence interval, RMSSD root mean square of successive differences in RR intervals, SDNN standard deviation of all normal to normal RR intervals, RR median 
duration of the RR interval, BMI body mass index
Abdominal adiposity (waist circumference ≥102 cm for men and ≥88 cm for women)
Characteristic RMSSD (ms) SDNN (ms) RR (ms)
Mean 95 % CI Mean 95 % CI Mean 95 % CI
Sex (%)
 Male 40.72 (39.07, 42.38) 34.20 (32.98, 35.43) 1010 (1003, 1016)
 Female 44.43 (43.08, 45.78) 35.34 (34.36, 36.32) 968 (963, 973)
Age group (%)
 18–24 63.33 (59.82, 66.85) 49.20 (46.76, 51.64) 981 (971, 991)
 25–34 50.37 (48.22, 52.52) 40.30 (38.61, 41.98) 988 (978, 998)
 35–44 37.56 (36.14, 38.97) 31.41 (30.27, 32.55) 985 (976, 993)
 45–54 30.32 (29.38, 31.26) 26.13 (25.39, 26.87) 994 (987, 1001)
 55–64 26.51 (25.39, 27.63) 23.59 (22.59, 24.58) 992 (984, 1001)
 65+ 27.59 (24.63, 30.54) 23.20 (20.71, 25.68) 1006 (991, 1022)
Obese (BMI ≥ 30 kg/m2)
 Yes 43.49 (42.09, 44.89) 35.55 (34.50, 36.61) 1001 (996, 1006)
 No 41.20 (39.33, 43.08) 33.49 (32.22, 34.76) 966 (959, 973)
Abdominal adiposity
 Yes 44.50 (42.92, 46.08) 36.64 (35.44, 37.83) 1010 (1004, 1016)
 No 40.89 (39.37, 42.42) 33.05 (31.98, 34.13) 967 (962, 973)
Current smoking
 Yes 42.07 (40.96, 43.17) 34.22 (33.44, 35.01) 985 (981, 990)
 No 44.72 (41.75, 47.68) 36.83 (34.63, 39.02) 998 (988, 1009)
Beta blocker use
 Yes 43.14 (41.97, 44.30) 35.24 (34.40, 36.07) 987 (982, 991)
 No 31.91 (28.80, 35.01) 24.84 (22.65, 27.03) 1042 (1024, 1060)
Non-hydropyridine calcium channel blocker use
 Yes 43.11 (41.96, 44.27) 35.16 (34.33, 35.98) 989 (984, 993)
 No 25.92 (22.42, 29.42) 22.14 (19.73, 24.56) 981 (959, 1003)
Sympathomimetic medication use
 Yes 42.76 (41.62, 43.91) 34.88 (34.07, 35.69) 990 (986, 995)
 No 43.04 (33.48, 52.59) 35.45 (28.13, 42.78) 936 (917, 954)
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Fig. 1 Mean (95 % confidence interval) of a RMSSD, b SDNN, and c RR by quartiles (Q) of glycemic homeostasis marker stratified by sex. Values are 
Q1 (lowest) to Q4 (highest). RMSSD root mean square of successive differences in RR intervals, SDNN standard deviation of all normal to normal RR 
intervals, RR median duration of the RR interval; HbA1c glycated hemoglobin, HOMA-IR homeostasis model assessment of insulin resistance
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SDNN and positively associated with heart rate, but not 
associated with RMSSD in a study among participants 
with normal fasting glucose levels [5]. In a healthy cohort 
free of diabetes, fasting insulin and fasting glucose levels 
were associated with reduced cardiac autonomic func-
tion measured by baroreflex sensitivity, but the asso-
ciation with fasting glucose was no longer significantly 
associated after adjusting for age, blood pressure and 
body mass index [13]. The patterns as reported above 
include HRV measured from 2  min to 24  h ECGs, and 
are similar to our results from 10 s ECGs. However, both 
fasting insulin and fasting glucose levels were associated 
with lower RMSSD, SDNN and RR in this study, with 
stronger associations among subgroups.
We add to the literature by reporting on the associa-
tions between HbA1c and HOMA-IR with reduced heart 
rate variability. A study among participants with normal 
fasting glucose levels showed that only HbA1c was asso-
ciated with reduced cardiac autonomic function defined 
as the lowest 25th percentile for SDNN and baroreflex 
sensitivity [4]. No associations were observed between 
fasting insulin and fasting glucose with SDNN and mean 
NN (RR interval). We found that HbA1c was associated 
with RMSSD, SDNN and RR among those with abdomi-
nal adiposity (WC ≥102  cm for men and ≥88  cm for 
women), but no associations were observed among indi-
viduals with waist circumferences below the sex-specific 
cut-points. Discrepancies in the association between 
Table 3 Adjusted associations of glucose homeostasis markers with RMSSD, SDNN and RR interval
Abdominal adiposity (waist circumference ≥102 cm for men and ≥88 cm for women)
RMSSD root mean square of successive differences in RR intervals, SDNN standard deviation of all normal to normal RR intervals, RR median duration of the RR interval, 
HbA1c glycated hemoglobin, HOMA-IR homeostasis model assessment of insulin resistance
a Model 1 includes gender, age groups (each as an indicator variable), Hispanic background, and medications: β-blocker, non-hydropyridine calcium channel blocker, 
sympathomimetics, and field center
b For fasting glucose, fasting insulin, and HOMA-IR, model 2 includes model 1 plus current smoking and waist circumference. For HbA1C, model 2 includes model 1 
plus current smoking
Outcome/exposure Unadjusted Model 1a Model 2b
β 95 % CI β 95 % CI β 95 % CI
RMSSD (ms)
 Fasting glucose (mg/dL) −0.65 (−0.77, −0.53) −0.20 (−0.33, −0.07) −0.16 (−0.28, −0.05)
 Fasting insulin (mU/L), men −0.45 (−0.66, −0.24) −0.43 (−0.62, −0.24) −0.44 (−0.62, −0.26)
 Fasting insulin (mU/L), women −0.06 (−0.20, 0.08) −0.13 (−0.24, −0.01) −0.14 (−0.27, −0.01)
 HbA1c, no abdominal adiposity −12.8 (−15.83, −9.78) 3.61 (0.26, 6.97) 3.22 (−0.09, 6.53)
 HbA1c, abdominal adiposity −16.5 (−20.09, −13.04) −3.57 (−6.74, −0.41) −3.62 (−6.75, −0.48)
 HOMA-IR, men −1.88 (−2.71, −1.05) −1.65 (−2.37, −0.92) −1.66 (−2.34, −0.97)
 HOMA-IR, women −0.49 (−1.03, 0.06) −0.55 (−1.03, −0.07) −0.58 (−1.10, −0.06)
SDNN (ms)
 Fasting glucose (mg/dL) −0.43 (−0.52, −0.34) −0.13 (−0.23, −0.04) −0.10 (−0.20, −0.01)
 Fasting insulin (mU/L), men −0.29 (−0.44, −0.15) −0.28 (−0.41, −0.15) −0.26 (−0.38, −0.13)
 Fasting insulin (mU/L), women −0.05 (−0.15, 0.05) −0.10 (−0.19, −0.01) −0.08 (−0.18, 0.02)
 HbA1c, no abdominal adiposity −9.11 (−11.44, −6.78) 2.29 (−0.20, 4.77) 1.98 (−0.48, 4.44)
 HbA1c, abdominal adiposity −11.8 (−14.42, −9.26) −2.56 (−4.94, −0.19) −2.60 (−4.96, −0.23)
 HOMA-IR, men −1.23 (−1.79, −0.67) −1.07 (−1.56, −0.58) −0.97 (−1.44, −0.49)
 HOMA-IR, women −0.37 (−0.77, 0.03) −0.43 (−0.79, −0.06) −0.35 (−0.77, 0.06)
RR (ms)
 Fasting glucose (mg/dL) −0.80 (−1.29, −0.31) −2.02 (−2.52, −1.52) −1.55 (−2.06, −1.04)
 Fasting insulin (mU/L), men −4.41 (−5.13, −3.69) −4.39 (−5.11, −3.67) −4.09 (−4.90, −3.29)
 Fasting insulin (mU/L), women −3.15 (−3.94, −2.36) −3.07 (−3.80, −2.34) −2.82 (−3.54, −2.09)
 HbA1c, no abdominal adiposity 19.58 (2.84, 36.32) 1.03 (−16.54, 18.61) −0.33 (−17.83, 17.18)
 HbA1c, abdominal adiposity −8.18 (−20.46, 4.11) −22.8 (−35.12, −10.55) −22.9 (−35.24, −10.72)
 HOMA-IR, men −17.2 (−20.07, −14.46) −17.3 (−20.15, −14.47) −16.0 (−19.18, −12.93)
 HOMA-IR, women −12.8 (−15.70, −10.03) −12.6 (−15.32, −10.03) −11.5 (−14.17, −8.91)
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measures of glucose metabolism and HRV between prior 
studies and our results could be related to differences in 
HRV methodology and the study populations since previ-
ous studies involved mostly older Caucasian participants. 
Additionally, there were no reports of whether the inves-
tigators examined effect modification by sex or adiposity.
Potential mechanisms of the sex differences in glucose 
homeostasis and cardiac autonomic function
There was a stronger association between fasting insulin 
and HOMA-IR with HRV among men compared with 
women. Sex differences in HRV among those without 
diabetes have not been well studied, but evidence among 
those with diabetes suggests that there are sex differences 
in nerve conduction [24]. Men tend to present symp-
toms of diabetic neuropathy earlier than women [25], 
and might be more susceptible to autonomic failure (as 
defined by e.g. low HRV) compared with women [26, 
27]. These observations indicate that men have earlier or 
stronger manifestations of reduced cardiac autonomic 
function compared with women, which could explain the 
effect modification by sex observed in this study.
Abdominal adiposity in cardiac autonomic function
HbA1c was only associated with HRV measures among 
those with abdominal adiposity defined as a high waist 
circumference. This is consistent with previous studies 
showing that visceral, or central, adipose tissue is more 
strongly associated with metabolic dysregulation, muscle 
sympathetic nerve activity [28, 29], autonomic nervous 
system activity [30], and HR [31]. The adipokine leptin is 
associated with autonomic dysfunction [32, 33], and may 
be stronger among those with higher levels of adipos-
ity [34]. HbA1c is a time-integrated marker of long-term 
glucose exposure, thus the observed association suggests 
that those with abdominal obesity and poor glycemic 
control are prone to have lower cardiac autonomic func-
tion, although we were not able to evaluate such a com-
plex relationship in this cross-sectional analysis.
Glucose homeostasis measures and modulation of cardiac 
autonomic function
The observed associations between glucose homeostasis 
measures with SDNN, RMSSD and RR suggest that insu-
lin resistance and impaired glycemic control adversely 
affect autonomic function; however, the temporal rela-
tionship between insulin resistance and poor glucose 
control with reduced cardiac autonomic activity has not 
been elucidated. Several mechanisms have been impli-
cated in the link between glucose homeostasis measures 
with reduced autonomic function. Insulin resistance 
could cause reduced autonomic function by triggering 
sympathetic nervous system activity [35, 36], suppressing 
vagal cardiac activity [37], and regulating energy bal-
ance and homeostasis [38–41]. An enhanced formation 
of advanced glycation end products and their associated 
cross-linking molecules [42] is also reported to be associ-
ated with autonomic nerve impairment and neuropathy 
in individuals with diabetes [43]. Although the mecha-
nisms that contribute to reduced cardiac autonomic 
function are not fully characterized, the evidence above 
indicates that insulin resistance and glucose metabolism 
are central factors.
Limitations
Our study had limitations that should be noted. We used 
ultra-short HRV measures without control for respira-
tion. Although guidelines from the Task Force of the 
European Society of Cardiology the North American 
Society of Pacing Electrophysiology recommend a 5-min 
recording for time domain HRV indices [19], ultra-short 
term measures of HRV have been shown to have high 
reproducibility [44] and their predictive validity has 
been described [45–50]. Time limitations precluded the 
acquisition of ECG records of longer duration, therefore 
only time domain indices were available. Thus, frequency 
domain indices to distinguish parasympathetic and sym-
pathetic modulation of cardiac autonomic activity and 
geometric measures that would allow for the assessment 
of different geometrical forms were not attempted. Lastly, 
we are unable to address the temporality of the observed 
associations given the cross-sectional nature of these 
analyses.
Conclusions
A comprehensive set of glucose homeostasis measures 
were associated with reduced autonomic activity in 
some subgroups of Hispanic/Latino adults without dia-
betes. The associations were stronger among men and 
in those with abdominal adiposity, offering clues for the 
pathophysiologic processes involved as well as opportu-
nity for identification of those at high risk before auto-
nomic control is manifestly impaired. While screening 
for reduced cardiac autonomic function is recommended 
for risk assessment in persons with diabetes, our results 
suggest that impairment in glucose homeostasis is associ-
ated with lower autonomic activity even before diabetes 
becomes clinically manifest. The longitudinal follow-up 
of this population can be expected to offer insights into 
the temporal relationships of glucose homeostasis meas-
ures with HRV, and its utility in risk stratification.
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